980 related articles for article (PubMed ID: 34374967)
1. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
[TBL] [Abstract][Full Text] [Related]
3. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Zekarias A; Watson S; Vidlin SH; Grundmark B
Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
[TBL] [Abstract][Full Text] [Related]
4. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.
Charan J; Kaur RJ; Bhardwaj P; Haque M; Sharma P; Misra S; Godman B
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):95-103. PubMed ID: 33252992
[No Abstract] [Full Text] [Related]
5. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Lee S; Yang JW; Jung SY; Kim MS; Yon DK; Lee SW; Kang HC; Dragioti E; Tizaoui K; Jacob L; Koyanagi A; Salem JE; Kostev K; Lascu A; Shin JI; Kim JH; Smith L
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7390-7397. PubMed ID: 34919240
[TBL] [Abstract][Full Text] [Related]
6. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
Jung SY; Kim MS; Li H; Lee KH; Koyanagi A; Solmi M; Kronbichler A; Dragioti E; Tizaoui K; Cargnin S; Terrazzino S; Hong SH; Abou Ghayda R; Kim NK; Chung SK; Jacob L; Salem JE; Yon DK; Lee SW; Kostev K; Kim AY; Jung JW; Choi JY; Shin JS; Park SJ; Choi SW; Ban K; Moon SH; Go YY; Shin JI; Smith L
Clin Transl Sci; 2022 Feb; 15(2):501-513. PubMed ID: 34719115
[TBL] [Abstract][Full Text] [Related]
8. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
[TBL] [Abstract][Full Text] [Related]
9. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
Singh A; Kamath A
Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
[No Abstract] [Full Text] [Related]
10. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.
Rezagholizadeh A; Khiali S; Sarbakhsh P; Entezari-Maleki T
Eur J Pharmacol; 2021 Apr; 897():173926. PubMed ID: 33549577
[TBL] [Abstract][Full Text] [Related]
11. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
12. Compassionate Use of Remdesivir in Children With Severe COVID-19.
Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A
Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
[TBL] [Abstract][Full Text] [Related]
14. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.
Kim MS; Jung SY; Lee SW; Li H; Koyanagi A; Kronbichler A; Dragioti E; Tizaoui K; Wasuwanich P; Hong SH; Ghayda RA; Yoo HW; Kim H; Jacob L; Salem JE; Kostev K; Shin YH; Kim SY; Gamerith G; Yon DK; Shin JI; Smith L
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1970-1972.e3. PubMed ID: 33940227
[TBL] [Abstract][Full Text] [Related]
15. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M
Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir for patients with COVID-19.
Wu PE; Morris AM
CMAJ; 2021 Jan; 193(4):E125. PubMed ID: 33408097
[No Abstract] [Full Text] [Related]
17. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898
[No Abstract] [Full Text] [Related]
18. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
Montastruc F; Thuriot S; Durrieu G
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2835-2836. PubMed ID: 32721580
[TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
20. Preliminary findings from stimulated spontaneous reporting of adverse drug reactions during COVID-19 pandemic: an experience from Ghana.
Darko DA; Seaneke SK; Sabblah GT; Ashie A; Asamoa-Amoakohene A; Ewudzie JS; Asa-Eck T; Agyei-Kwame E; Dwamena F; Mensah J; Boateng J
Ghana Med J; 2020 Dec; 54(4 Suppl):62-70. PubMed ID: 33976443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
